

Selected Clinical Trials – Currently Open

(Updated December 2019)

Most clinical trials limit enrollment to only ACC patients with advanced disease (many measurable tumors). Increasingly, only patients with progressive disease (growing tumors) are being included in ACC studies. Each patient’s decision to enter a clinical trial is very personal and will be based on a blend of the disease’s progression, the treatment’s anticipated effectiveness, the patient’s tolerance of side effects, financial constraints and travel limitations. Each situation is unique and should be discussed with a knowledgeable physician.

Table 1. Clinical Trials Recruiting All ACC Patients

Compound	Target(s)	Institution(s)	Location(s)	Scientific Rationale	Info Link	Contact(s)
Rivoceranib (Apatinib)	VEGFR	UCSF	San Francisco, CA, USA	Strong	View	Steven Norton, PhD 1-801-303-7440 ext 275 steven.norton@lskbiopharma.com
APG-115 with or without Carboplatin	MDM2	University of Michigan	Ann Arbor, MI, USA	Strong	View	Paul L Swiecicki, MD 1-734-647-1017 pswiecic@med.umich.edu Ryan Drzewicki ryandrze@med.umich.edu
Axitinib (Inlyta) and Avelumab (Bavencio)	VEGFR, PDGFR, KIT and PD-L1 Immunotherapy	MD Anderson	Houston, TX, USA	Strong	View	Renata Ferrarotto 1-713-792-6363
MYB Vaccine and BGB-A317	MYB and PD-1 Immunotherapy	Peter MacCallum Cancer Centre	Melbourne, Australia	Strong	View	Jayesh Desai +61 38559 7810 jayesh.desai@petermac.org
Pembrolizumab and Docetaxel	PD-1 Immunotherapy	University of Chicago	Chicago, IL, USA	Solid	View	Alexander Pearson, MD, PhD apearson5@medicine.bsd.uchicago.edu
Nivolumab and Ipilimumab and Radiation	PD-1 And CTLA-4 Immunotherapy	University of Washington	Seattle, WA, USA	Solid	View	Susan Masterson 1-206-606-7445 smasters@seattlecca.org
Chidamide	HDAC	Chinese Academy of Medical Sciences	Beijing, China	Solid	View	Mei Dong +86-10-87788130 Dongmei030224@163.com
Chidamide and Cisplatin	HDAC	Fudan University	Shanghai, China	Solid	View	Kai Xue, MD 021-64175590 xuekaishanghai@126.com
Apatinib and Proton Radiation (for inoperable or residual ACC tumors)	VEGFR	Shanghai Proton and Heavy Ion Center	Shanghai, China	Strong	View	Lin Kong, MD lin.kong@sphic.org.cn Jiyi Hu, MD jiyi.hu@sphic.org.cn



Table 2. Clinical Trials for ACC Patients with Activating NOTCH Alterations

Compound	Target(s)	Institution(s)	Location(s)	Scientific Rationale	Info Link	Contact
AL101	NOTCH	Ayala Pharmaceuticals	Calgary, Alberta, Canada Hamilton, Ontario, Canada London, Ontario, Canada Copenhagen, Denmark Bordeaux, France Lyon, France Villejuif, France Barcelona, Spain Madrid, Spain Boston, MA, USA Houston, TX, USA Miami, FL, USA New York, NY, USA Tampa, FL, USA Seattle, WA, USA	Strong	View	View Info Link for details on each site
CB-103	NOTCH	Cellestia Pharmaceuticals	Amsterdam, Netherlands Maastricht, Netherlands Utrecht, Netherlands Barcelona, Spain Madrid, Spain Bellinzona, Switzerland	Strong	View	Pavel Pisa, MD pavel.pisa@cellestia.com

Table 3. “Basket” Clinical Trials Incorporating Tumor Profiling

Compound	Target(s)	Institution(s)	Location(s)	Scientific Rationale	Info Link	Contact
NCI-MATCH	Multiple targets	National Cancer Institute	Over 1,000 locations in USA	Solid	View	View Info Link for details on each site
NCI-DART (Nivolumab and Ipilimumab for NCI-MATCH patients with rare tumors without targetable alterations)	PD-1 and CTLA-4 Immunotherapy	National Cancer Institute	Over 600 locations in USA	Solid	View	View Info Link for details on each site
ASCO TAPUR	Multiple targets	American Society of Clinical Oncology	USA (MI, NC; eventually national)	Solid	View	Pam Mangat, MS pam.mangat@asco.org
Drug Therapies for Salivary Gland Cancers Based on Testing of Genes (for salivary gland cancer patients; only Canadian patients are eligible)	Multiple targets	University Health Network, Toronto	Toronto, Ontario, Canada	Solid	View	Albiruni Razak, M.D. 1-416-946-4501 ext 3428